ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II)

S M C De Sousa; M Stowasser; J Feng; A W Schreiber; P Wang; C N Hahn; R D Gordon; D J Torpy; H S Scott; L Gagliardi

doi:10.1038/jhh.2017.71

ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II)

J Hum Hypertens. 2017 Dec;31(12):857-859. doi: 10.1038/jhh.2017.71. Epub 2017 Oct 12.

Authors

S M C De Sousa^{1

2

3}, M Stowasser⁴, J Feng⁵, A W Schreiber^{5

6}, P Wang⁵, C N Hahn^{2

3}, R D Gordon⁴, D J Torpy^{1

2}, H S Scott^{2

3

5

6

7}, L Gagliardi^{1

2

3}

Affiliations

¹ Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, Australia.
² School of Medicine, University of Adelaide, Adelaide, Australia.
³ Centre for Cancer Biology, Department of Genetics and Molecular Pathology, an SA Pathology and University of South Australia alliance, Adelaide, Australia.
⁴ Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Greenslopes and Princess Alexandria Hospitals, Brisbane, Australia.
⁵ ACRF Cancer Genomics Facility, Centre for Cancer Biology, SA Pathology, Adelaide, Australia.
⁶ School of Biological Sciences, University of Adelaide, Adelaide, Australia.
⁷ School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia.

PMID: 29022889
DOI: 10.1038/jhh.2017.71

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Armadillo Domain Proteins
DNA Mutational Analysis
Exome Sequencing
Female
Genetic Predisposition to Disease
Germ-Line Mutation*
Heredity
Humans
Hyperaldosteronism / diagnosis
Hyperaldosteronism / genetics*
Male
Middle Aged
Pedigree
Phenotype
Risk Factors
Tumor Suppressor Proteins / genetics*

Substances

ARMC5 protein, human
Armadillo Domain Proteins
Tumor Suppressor Proteins

Supplementary concepts

Hyperaldosteronism, Familial, Type II